Gates Foundation To Invest Up To $140M In Implantable HIV Prevention Device Research

Quartz: Bill and Melinda Gates are now backing a tiny implantable drug pump designed to prevent HIV infection
“…A daily dose of PrEP can reduce the risk of contracting HIV from sex by more than 90 percent. Getting patients to take the drug daily, a problem with most chronic diseases, is critical for preventing HIV effectively. Hoping to address this issue, the Bill & Melinda Gates Foundation is investing $140 million to help Intarcia Therapeutics, a Boston-based biopharmaceutical company, develop a tiny implantable drug pump…” (Bagri, 12/31).

Wall Street Journal: Gates Foundation to Invest Up to $140 Million in HIV Prevention Device
“…The matchstick-size pump … can hold six or 12 months’ supply of medicine and is designed to deliver microdoses continuously to patients, ensuring they stay on the treatment. The new investment, which Intarcia announced [December 29], comes amid a flurry of fresh efforts to develop HIV prevention strategies…” (Winslow, 12/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.